PRACTICAL DERMATOLOGY

Multidisciplinary Management of the Adverse Effects of Apremilast

E. Daudén Tello, a,∗ J. Alonso Suárez, b E. Beltrán Catalán, c C. Blasco Maldonado, d M.C. Herrero Manso, e A. Jiménez Morales, f I. Marín-Jiménez, g M.D. Martin-Arranz, h A. García-Merino, i J. Porta Etessam, j M.A. Rodríguez-Sagrado, k J. Rosas Gómez de Salazar, l E. Trujillo Martín, m L. Salgado-Boquete n

a Servicio de Dermatologia, Hospital Universitario La Princesa, Madrid, Spain
b Servicio de Dermatologia, Hospital Universitario Virgen de la Victoria, Málaga, Spain
c Servicio de Reumatología, Hospital Parc Salut del Mar, Barcelona, Spain
d Unidad de Enfermería, Servicio de Dermatología, Hospital Universitario Puerta de Hierro, Madrid, Spain
e Unidad de Enfermería, Servicio de Reumatología, Hospital Universitario 12 de Octubre, Madrid, Spain
f Servicio de Farmacia, Hospital Universitario Virgen de las Nieves, Granada, Spain
g Unidad de El-I-CEIMI-Servicio de Aparato Digestivo, Hospital Gregorio Marañón, Madrid, Spain
h Servicio de Aparato Digestivo, Hospital Universitario La Paz, Grupo de Inmunidad Innata, Instituto de Investigación IdiPaz, Madrid, Spain
i Servicio de Neurología, Hospital Universitario Puerta de Hierro, Madrid, Spain
j Servicio de Neurología, Hospital Clínico San Carlos, Madrid, Spain
k Servicio de Farmacia, Hospital Universitario Ramón y Cajal, Madrid, Spain
l Sección de Reumatología, Hospital Marína Baixa, Villajoyosa, Alicante, Spain
m Servicio Reumatología, Hospital Universitario de Gran Canaria, Las Palmas de Gran Canaria, Spain
n Servicio de Dermatología, Complejo Hospitalario Universitario, Pontevedra, Spain

Received 9 April 2020; accepted 22 August 2020
Available online 31 December 2020

KEYWORDS
Apremilast;
Psoriasis;
Headache;
Diarrhea;
Nausea;
Adverse effects

Abstract We present a series of general and specific recommendations based on pathophysiology considerations for managing the most common adverse effects of apremilast that lead to treatment discontinuation: diarrhea, nausea, and headache. The recommendations are based on a review of the literature and the experience of a multidisciplinary team of 14 experts including dermatologists, rheumatologists, neurologists, gastroenterologists, pharmacists, and nurses. We propose a series of simple algorithms that include clinical actions and suggestions for pharmacologic treatment.


∗ Corresponding author.
E-mail addresses: estebandauden@gmail.com, esteban.dauden@uam.es (E. Daudén Tello).

1578-2190/© 2020 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Since its approval by the European Commission in 2015, apremilast has been used in the treatment of psoriasis and psoriatic arthritis in adult patients.1-5 The agent is an oral inhibitor of phosphodiesterase 4 (PDE-4) and has a good safety profile with a low incidence of adverse effects; those that do occur are mainly of mild or moderate severity and largely involve the digestive tract.1,2 The incidence of these adverse effects is higher during the first 2 months of treatment and then decreases notably, particularly from the second year of use onwards (Table 1).5,6 They often resolve without need for medical intervention or dose adjustment.7 Although the rate of treatment discontinuations due to adverse effects was less than 2% during clinical development,1,2 a higher rate of apremilast discontinuations has been reported in clinical practice (Table 2).8

In order to assess the strategies available for management of adverse effects that most often lead to treatment discontinuation in patients with psoriasis and/or psoriatic arthritis (diarrhea, nausea, and headache), a multidisciplinary committee of experts in rheumatology, dermatology, neurology, gastroenterology, hospital pharmacy, and nursing, belonging to 14 Spanish hospitals, conducted a broad review of the literature, with special focus on the general pathophysiology of each adverse effect from the point of view of their particular specialty. After considering this information and personal experience, a series of consensus recommendations were made.

Headache

Drug-induced headaches are a neurological process triggered by activation of pain-modulating structures in the central or peripheral nervous system. A migraine attack can be triggered through action on different structures involved in its pathophysiology or by altering the antinociceptive structures that are responsible for migraine resolution. In the framework of pathophysiology of migraines, in recent years, the importance of neuropeptides that participate in genesis of pain and other typical symptoms of migraine has been increasingly recognized. Release of neuropeptides leads to nerve fiber sensitization (neuronal hyperexcitability), thereby enhancing central and peripheral pain and inflammation.9 Calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating peptide (PACAP), and their respective receptors are one of the main targets for new migraine therapies.10

Although the mechanism that triggers headache after administration of PDE-4 inhibitors has not been elucidated, it could be related to release of peptides that induce symptoms similar to migraine. The participation of PACAP and other neuropeptides could be responsible for the appearance of these symptoms, such that we might be facing 2 situations: 1) patients with migraine who see their pain exacerbated, whether in intensity or frequency, and 2) patients who have not suffered from headache and who start with a throbbing headache with sensitization (pathophysiology similar to migraine) or a headache with a different profile.

Patients With History of Headache Before Treatment With Apremilast

For patients with a history of migraine, there is the option of administering preventive treatment 2 weeks before starting apremilast therapy, as later administration may lead to a delay in the resolution of symptoms. Melatonin, at a dose of 3 mg/mg, could be a good option for preventive treatment,11 with triptanes as an option in the event of a migraine attack (Fig. 1, Table 3). Sumatriptan, at a dose of 25-100 mg/day, is indicated for acute treatment of intermittent migraine, with or without aura. If the patient responds after the first dose, and symptoms recur, a second dose could be administered in the following 24h if more than 2h have elapsed since the first dose (maximum 300 mg/day). Adverse
Table 1  Frequency of Adverse Drug Reactions Reported During Long-term Follow-up of Apremilast Treatment.

<table>
<thead>
<tr>
<th></th>
<th>Year 1, %</th>
<th>Year 2, %</th>
<th>Year 3, %</th>
<th>Year 4, %</th>
<th>Year 5, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea Psoriasis</td>
<td>17.3</td>
<td>2.3</td>
<td>1.7</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>PsA</td>
<td>15.7</td>
<td>3.8</td>
<td>2.7</td>
<td>1.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Nausea Psoriasis</td>
<td>15.7</td>
<td>0.8</td>
<td>1.5</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>PsA</td>
<td>15.0</td>
<td>2.1</td>
<td>2.3</td>
<td>0.7</td>
<td>0.3</td>
</tr>
<tr>
<td>Headache Psoriasis</td>
<td>6.3</td>
<td>0.9</td>
<td>1.7</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>PsA</td>
<td>10.4</td>
<td>3.3</td>
<td>2.7</td>
<td>2.0</td>
<td>0.5</td>
</tr>
<tr>
<td>Tension headache Psoriasis</td>
<td>9.0</td>
<td>1.2</td>
<td>1.2</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>PsA</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

Abbreviations: NE, not evaluated; PsA, psoriatic arthritis.
Adapted from Crowley et al. and Kavanaugh et al.

Table 2  Frequency of Adverse Drug Reactions and Treatment Discontinuation of Apremilast for the Treatment of Psoriasis in Clinical Trials and Clinical Practice.

<table>
<thead>
<tr>
<th></th>
<th>Diarrhea</th>
<th>Nausea</th>
<th>Headache</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency of adverse effect, %</td>
<td>CT 17.8</td>
<td>16.6</td>
<td>13.1</td>
</tr>
<tr>
<td>Treatment discontinuation, %</td>
<td>CP 16.3</td>
<td>14.4</td>
<td>15.9</td>
</tr>
</tbody>
</table>

Abbreviations: CP, clinical practice; CT, combined analysis of clinical trials.
Adapted from Ighani et al.

MANAGEMENT OF HEADACHE*

History of headache prior to treatment with apremilast

- Preventive treatment for headache
  - Melatonin
  - Amitriptyline
  - Beta-blockers
  - Triptans (in event of crisis)

Headache with onset after starting treatment with apremilast

- Throbbing component
- Worsens with activity
- Photophobia

Migraine type

- NSAID
- Triptanes

Tension type

- Paracetamol
- Metamizole
- NSAID

Figure 1  Algorithm for management of headache induced by apremilast.

*As an alternative to these treatments, lengthening the initial escalation regimen of apremilast by 1–2 weeks and/or lowering the dose (30 mg/day) can be considered. This strategy may help lower the rate of headache observed in the early phases of treatment.

Effects that have been reported frequently for sumatriptan include general disorders (weakness, fatigue, pressure) and musculoskeletal disorders (heaviness, myalgia), which are generally transient and of mild or moderate intensity. Other reactions include dyspnea, increased blood pressure, dizziness, somnolence, and sensory abnormalities. In the event of lack of response to sumatriptan, treatment with paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended.

Alternatively, other preventive therapies include amitriptyline or beta-blockers, depending on the profile of the patient. The initial recommended dose of amitriptyline is 10–25 mg, before going to bed, with an increase of 10–25 mg every 3–7 days, depending on the tolerance
Table 3  Management of Headache, Diarrhea, and Nausea Caused by Apremilast Treatment.

<table>
<thead>
<tr>
<th>Prior Considerations</th>
<th>Preventive Treatment</th>
<th>Pharmacological Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Headache</strong> Patients with history of headache before starting apremilast treatment</td>
<td><strong>Only in case of headache prior to treatment</strong></td>
<td><strong>Migraine type:</strong></td>
</tr>
<tr>
<td></td>
<td>• Melatonin: 3 mg/day</td>
<td>• NSAID: naproxen 550 mg + 275 mg every 6–8 h; ibuprofen 1.2–1.8 g/day in several doses</td>
</tr>
<tr>
<td></td>
<td>• Amitriptyline: 10–25 mg/day with increase every 3–7 d (maximum 25–75 mg/day)</td>
<td>• Triptanes: sumatriptan 25–100 mg/day</td>
</tr>
<tr>
<td></td>
<td>• Beta-blockers: propranolol 40 mg 2–3 times/day with weekly increase to 80–160 mg/day (maximum 240 mg/day)</td>
<td><strong>Tension type:</strong></td>
</tr>
<tr>
<td></td>
<td>• Triptanes (in case of migraine attack): sumatriptan 25–100 mg/day</td>
<td>• Paracetamol: 500 mg every 4–6 h or 1 g every 8 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Metamizole: 575 mg 3–4 times/day (maximum 7 days)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• NSAID: naproxen 550 mg + 275 mg every 6–8 h; ibuprofen 1.2–1.8 g/day in several doses</td>
</tr>
<tr>
<td><strong>Diarrhea</strong></td>
<td><strong>Frequent smaller meals</strong></td>
<td><strong>Racecadotril:</strong> 100 mg every 4–6 h for 7 days</td>
</tr>
<tr>
<td></td>
<td>• Limit liquid intake during meals</td>
<td>• Loperamide: 2 tablets (4 mg) and then 1 after every deposition (maximum 4 tablets/day for 2 days)</td>
</tr>
<tr>
<td></td>
<td>• Consider avoiding dairy products, caffeine, and artificial sweeteners</td>
<td>• Codeine: 1–2 tablets (21.4 mg/tablet) every 6 h (maximum 6 tablets/day for 3 days)</td>
</tr>
<tr>
<td><strong>Nausea</strong> Relationship with headache caused by apremilast treatment</td>
<td><strong>Frequent smaller meals</strong></td>
<td><strong>Ondansetron:</strong> 8 mg before first apremilast treatment and then every 12 h</td>
</tr>
<tr>
<td></td>
<td>• Limit liquid intake during meals</td>
<td>• Metoclopramide: 10 mg, 3 times/day</td>
</tr>
<tr>
<td></td>
<td>• Avoid activity after eating</td>
<td>• For a maximum of 5 days</td>
</tr>
</tbody>
</table>

^ Beta-blockers can induce or exacerbate psoriasis.

of the patient (maximum 25–75 mg/day). The analgesic effect is usually felt after 2–4 weeks of treatment, and the most frequent adverse effects include: aggression, somnolence, dizziness, headache, blurry vision, palpitations, tachycardia, constipation, nausea, dry mouth, weight gain, nasal congestion, hyperhidrosis, and orthostatic hypotension. Of the beta-blockers, propranolol is indicated for prophylactic treatment of migraine with an initial dose of 40 mg 2 or 3 times a day, with increments by the same amount over weekly intervals depending on the response of the patient up to 80–160 mg/day (maximum 240 mg/day). It should be remembered that administration of propranolol may cause fatigue, bradycardia, cold hands and feet, Raynaud phenomenon, and sleep disorders. It should also be remembered that beta-blockers, and propranolol in particular, belong to the group of drugs able to induce or exacerbate psoriasis. A careful assessment of the benefit/risk profile is therefore important prior to recommending its use.

**Patients With Headache That Presents After Starting Treatment With Apremilast**

In patients who present with headache after administration of apremilast, 3 differential characteristics of the type of headache should be considered: 1) the throbbing component; 2) whether it worsens with activity and/or head movement; and 3) if photophobia is present (Fig. 1). The presence of these 3 components corresponds to a profile of meningeal inflammation denoted migraine type. Therapeutic intervention is only necessary when the headaches have an impact on the quality of life of the patient. In this case, treatment for this type of headache is based on administration of NSAIDs, such as for example naproxen and ibuprofen, or triptanes (Table 3). As a general regimen, daily doses of naproxen range from 550 mg to 1.1 g, with a recommended starting dose of 550 mg followed by 275 mg every 6–8 h, depending on the intensity of the headache. The daily recommended dose of ibuprofen is 1.2–1.8 g, administered over several doses and without exceeding a dose of 2.4 mg/day. In contrast, if the headache is of the tension type, treatment with paracetamol or metamizole is recommended, with the additional use of an NSAID also an option. A regimen of 500 mg of paracetamol every 4–6 h or 1 g every 8 h is recommended, without exceeding the maximum dose of 3 g/day. Metamizole can be administered at a dose of 575 mg (a capsule) 3 or 4 times a day for a week, without exceeding the maximum dose of 6 capsules/day. Reactions of hypotension can present during or after treatment with metamizol.
Diarrhea

Diarrhea caused by PDE-4 inhibitors is considered of a secretory nature. The increase in intracellular cAMP caused by PDE-4 inhibition can trigger intestinal secretion through activation of chloride channels in the apical membrane of the enterocytes and inhibition of NaCl absorption. Different isoforms of PDE-4 interact with the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel implicated in secretion and homeostasis, whose hyperactivation may give rise to secretory diarrhea. Through protein kinase A (PKA), cAMP also promotes intestinal secretion by activation of different membrane proteins in the enterocytes, such as K+ and anion channels and NaKCl transporters. In addition, it has been suggested that early resolution of symptoms associated with diarrhea caused by apremilast (in approximately 2 weeks) could be due to upregulation of other PDEs in the intestine, as a compensatory mechanism for PDE-4 inhibition.

As described for headache, the best strategy for appropriate management of gastrointestinal adverse effects, when considered necessary, is to administer a treatment that is thought to act effectively on the underlying pathophysiology. Preventive measures such as administration of apremilast during meals, avoiding excessive liquid intake or intake of caffeine and sweeteners could reduce or delay the onset of symptoms of secretory diarrhea caused by apremilast. Although not fully accepted, it is possible that administration of probiotics could reduce the symptoms associated with gastrointestinal intolerance, thus permitting better therapeutic compliance and a lower discontinuation rate. On the other hand, fiber supplements and administration of bismuth subsalicylate may be used as a complementary therapy to reduce water loss and the number of depositions (Fig. 2, Table 3). In any case, it is recommended to follow a simple treatment regimen that is not accompanied by major changes in the patient’s lifestyle.

Apremilast-induced diarrhea is usually self-limiting and resolves in the first few weeks of treatment. If pharmaco-
logical intervention is deemed necessary, secretory diarrhea could be treated effectively with racecadotril, an anti-secretory agent that can be used for the treatment of apremilast-induced diarrhea (Fig. 2, Table 3). Racecadotril acts by inhibiting intestinal encephalinase, thus reducing water and electrolyte secretion to the intestinal lumen. Administration of 100 mg every 8 h, preferably before meals, has been shown to shorten the duration of diarrhea symptoms, reduce the number of depositions, and reduce the need for rehydration. This regimen is recommended to continue for 7 days, until attaining 2 depositions/day. Adverse skin reactions, generally moderate, have been reported, along with headache and cases of hypersensitivity/angioneurotic edema in patients in treatment with racecadotril. Other pharmacological options for the treatment of diarrhea caused by apremilast include loperamide and codeine. Loperamide is indicated for treatment of acute diarrhea with an initial dose of 4 mg (2 tablets), continuing with an additional tablet for each additional dose, for a maximum of 2 days and 4 tablets/day. Gastrointestinal disorders (nausea and dysgeusia) have often been reported after treatment with loperamide. If clinical improvement is not observed in 48 h, or if symptoms of constipation, ileus, or abdominal distension appear, administration of loperamide should be discontinued. In the case of treatment with codeine, the recommended regimen is 1 tablet (21.4 mg) every 6 h; this can be increased to 2 tablets per administration, for a maximum duration of 2 days, administering 6 tablets/day. Administration of codeine can cause somnolence and alcohol intake should be avoided during treatment, as this can enhance the depressor effect on the CNS.

Nausea

Nausea induced by PDE-4 inhibitors appears to be triggered by central and peripheral mechanisms. This adverse effect has been associated with lack of selectivity of PDE-4 inhibitors for the different isoforms (A, B, C, D) expressed in different cell types. Specifically, the PDE-4 D isoform is expressed in neurons of the area postrema, where the chemoreceptor trigger zone that links with the vomit cen-
Table 4  Key Points and General Recommendations in the Prevention and Management of the Main Adverse Effects Caused by Apremilast (Fig. 4).

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>The onset of adverse effects caused by apremilast therapy usually occurs in the first 2–4 weeks of treatment, and they are usually self-limiting and resolve spontaneously in the initial phases of treatment.</td>
</tr>
<tr>
<td>If pharmacological treatment is required and if the diarrhea, nausea, or headache persist despite treatment, negatively impacting the patient’s quality of life, the options of referring him or her to the gastroenterology or neurology department could be considered.</td>
</tr>
<tr>
<td>The decision to refer the patient to another department and/or discontinue treatment with apremilast should be taken on an individual basis, taking into account the expectations of apremilast treatment compared with other available drugs, as well as the delay at each center in obtaining multidisciplinary care or care in another department.</td>
</tr>
<tr>
<td>As an alternative to the treatments considered above, lengthening the initial apremilast escalation regimen by 1–2 weeks and/or using lower doses (30 mg/day) could help reduce adverse effects that develop in early phases of treatment.</td>
</tr>
<tr>
<td>With the aim of avoiding early discontinuation of treatment by the patient, it is recommended to provide him or her with sufficient information on the possible adverse effects (type, estimated duration, and treatment) before starting therapy with apremilast.</td>
</tr>
<tr>
<td>Performing a follow-up visit at 1 month after starting therapy helps minimize and promptly resolve adverse effects, improving the patient’s therapeutic compliance.</td>
</tr>
<tr>
<td>An appropriate communication system (telephone contact, nursing visit, support service, etc.) will help the patient have ready access to health care professionals to resolve doubts about management of possible adverse effects.</td>
</tr>
<tr>
<td>It is recommended that the patient is sufficiently well informed and is provided with the prophylactic and therapeutic options available before discontinuing treatment.</td>
</tr>
<tr>
<td>Both the management of adverse effects and patient education can be performed in a multidisciplinary setting with coordination between the dermatology and rheumatology departments, nursing, and hospital pharmacy.</td>
</tr>
</tbody>
</table>

The possibility should also be considered that nausea is not a direct result of apremilast treatment but rather a side effect of the neurological adverse effects described above. It is therefore recommended to evaluate each case individually, and tailor management of the adverse effect that has triggered the symptoms in the first place. Metoclopramide is also indicated for the treatment of nausea and vomiting induced by acute migraine, and can be administered in combination with oral analgesics to improve absorption of these analgesics.34

General Recommendations

Taking into consideration the above, a series of general recommendations are derived to facilitate the prevention and management of possible adverse effects caused by apremilast in clinical practice (Fig. 4, Table 4).

Adverse effects caused by apremilast should be managed in a multidisciplinary setting. Optimization of their management would no doubt be of clinical benefit to patients affected by these adverse effects.

Conflicts of Interest

Esteban Daudén: advisory board member, consultant, grant recipient, research support, participation in clinical trials, speaker fees with the following pharmaceutical companies: Abbott/AbbVie, Almirall, Amgen, Biogen, Celgene, Janssen-Cilag, Leo Pharma, Lilly, MSD, Novartis, and Pfizer.

Jorge Alonso Suárez: advisory board member, consultant, grant recipient, research support, participation in clinical trials, speaker fees with the following pharmaceutical companies: AbbVie, Almirall, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Celgene, Lilly.

M. Carmen Herrero Manso: consultancy, courses, book chapters, or congress attendance with UCB Pharma, Celgene, MSD, Pfizer, Mylan, BMS, AbbVie, Janssen, Sandoz, Gedeon Richter, Novartis, Lilly, Gebro, Nordic.

Ignacio Marín-Jiménez: consultancy, support for investigations or congress attendance with: AbbVie, Amgen, Celgene, Dr. Falk Pharma, Faes Farma, Ferring, Fresenius, Janssen, MSD, Pfizer, Sandoz, Takeda, and UCB-Pharma.

M. Dolores Martín-Arranz: Advisory Board member and support for investigation with the following pharmaceutical companies: MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Shire Pharmaceuticals, Tillotts Pharma, Faes Farma.

Miguel A. Rodríguez-Sagrado: renumerated activities for AbbVie, Biogen, Celgene, Gilead, Intercept, Janssen, Merck-Serono, MSD, Novartis, Roche, Sandoz, Tesaro, and ViIV.

José Rosas Gómez de Salazar: Advisory Board member: AbbVie, Celgene, Grifols, Janssen, Lilly, Pfizer. Speakers fees: Amgen, Grifols, Janssen, Lilly, MSD, Novartis, Pfizer, Stada.
Laura Salgado-Boquete: advisory board member, consultant, grant recipient, research support, participation in clinical trials, speaker fees from the following pharmaceutical companies: AbbVie, Almirall, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD-Schering-Plough, Celgene, Lilly.

The remaining authors declare that they have no conflicts of interest.

References
27. Ficha técnica Codeisan®. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); 2018 [Accessed March 2020].